Vertex and Bristol-Myers agree to run Phase 2 All-Oral
Studies of VX-135 in Combination with Daclatasvir (BMS-7900522) for the Treatment of
Hepatitis C. This is good news.
This is what you have been saying for almost two years.
~ Meaning that Third has been two years ahead of what this company is doing.